AstraZeneca has received Japanese regulatory approval for Faslodex (fulvestrant) 500mg, an oestrogen receptor antagonist for the treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer.

Faslodex disrupts oestrogen signalling, causing down-regulation of the oestrogen receptors in the tumour. This can not only reduce the growth and spread of the cancer, but also to reduce or delay resistance to treatment.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The results of a Phase III study led to the approval of Faslodex 500mg in Europe in March 2010 and the US in September 2010.

AstraZeneca Global Commercial Organisation executive vice-president Tony Zook said that metastatic breast cancer treatment primarily aims to prevent disease progression besides maintaining quality of life and Faslodex 500mg will provide women with better control over the disease.

It plans to introduce Faslodex 500mg in Japan by the end of 2011, the company said.

See Also:

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.